Is oral health correlated with skeletal phenotype in primary metabolic bone diseases? A preliminary report of the Greek experience

Abstract Renal osteodystrophy (ROD), a group of metabolic bone diseases secondary to chronic kidney disease (CKD), still represents a great challenge to nephrologists. Its management is tailored by the type of bone lesion - of high or low turnover - that cannot be accurately predicted by serum biomarkers of bone remodeling available in daily clinical practice, mainly parathyroid hormone (PTH) and alkaline phosphatase (AP). In view of this limitation, bone biopsy followed by bone quantitative histomorphometry, the gold-standard method for the diagnosis of ROD, is still considered of paramount importance. Bone biopsy has also been recommended for evaluation of osteoporosis in the CKD setting to help physicians choose the best anti-osteoporotic drug. Importantly, bone biopsy is the sole diagnostic method capable of providing dynamic information on bone metabolism. Trabecular and cortical bones may be analyzed separately by evaluating their structural and dynamic parameters, thickness and porosity, respectively. Deposition of metals, such as aluminum and iron, on bone may also be detected. Despite of these unique characteristics, the interest on bone biopsy has declined over the last years and there are currently few centers around the world specialized on bone histomorphometry. In this review, we will discuss the bone biopsy technique, its indications, and the main information it can provide. The interest on bone biopsy should be renewed and nephrologists should be capacitated to perform it as part of their training during medical residency.

Download Full-text

Review of certain articles of the American society of bone and mineral research (ASMBR) annual congress 2019

Osteoporosis and Bone Diseases ◽

10.14341/osteo12466 ◽

2020 ◽

Vol 22 (4) ◽

pp. 12-18

Author(s):

Zhanna E. Belaya

Keyword(s):

New York ◽

Bone Diseases ◽

Columbia University ◽

Mineral Research ◽

Metabolic Bone Diseases ◽

Relevant Today ◽

Metabolic Bone ◽

The Us ◽

Annual Congress ◽

American Society

The annual congress of the American Society of Bone and Mineral Research (ASBMR) presents the most significant results among the basic and clinical research in the field of osteoporosis and other metabolic bone diseases. Professor of Medicine John Bilezikian, M.D., Columbia University College of Physicians and Surgeons New York, New York and Lynda F. Bonewald Ph.D. Director, Indiana Center for Musculoskeletal Health, Indianapolis, Indiana, every year present the most outstanding abstracts before the ASBMR. However, not all of these researches are relevant for Russia, as some of them relates to the epidemiology and pharmacoeconomics of osteoporosis specifically in the US. This review presents only a very limited selection of congress abstracts, combined on topics that seem relevant today.

Download Full-text

Musculoskeletal Ultrasound in Rheumatology – New Horizons

Folia Medica ◽

10.3897/folmed.62.e47772 ◽

2020 ◽

Vol 62 (1) ◽

pp. 7-16

Author(s):

Tanya L. Sapundzhieva ◽

Rositsa Karalilova ◽

Anastas Batalov

Keyword(s):

Imaging Modality ◽

Connective Tissue Diseases ◽

Bone Diseases ◽

Musculoskeletal Ultrasound ◽

Diagnostic Process ◽

Skin Thickness ◽

Imaging Method ◽

Metabolic Bone Diseases ◽

New Horizons ◽

Metabolic Bone

Musculoskeletal ultrasound is a non-ionizing, cheap, reproducible, reliable imaging method, well accepted by the patients, that plays an important role in daily rheumatology practice. It can be used to assess joint and periarticular involvement, including tendon, bursae, enthesis, skin thickness, nails, lung and large vessels. Musculoskeletal ultrasound is more sensitive than physical examination, improves the diagnostic process, monitoring of treatment response, the accuracy of joint and soft tissue injections. It has proved its role as an important imaging modality in a number of rheumatic diseases – inflammatory joint diseases, systemic connective tissue diseases, large-vessel vasculitides, and degenerative and metabolic bone diseases.

Download Full-text